Next 10 |
Lakeland Industries Inc. (LAKE) is expected to report $0.3 for Q4 2024 Sekisui House Ltd. ADR (SKHSY) is expected to report for Q4 2024 Hingham Institution for Savings (HIFS) is expected to report for Q1 2024 GENFIT S.A. (GNFT) is expected to report for Q4 2023 Jewett-Cameron Trad...
2024-04-05 08:29:54 ET See the biggest morning stock movers . Read the full article on Seeking Alpha For further details see: Altice USA, Genfit, Brooge Energy among premarket losers' pack
2024-03-08 13:46:51 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alpha’s Quant Rating on Inventiva Historical earnings data for ...
2024-02-16 13:52:08 ET More on Inventiva Inventiva reports 9M results Seeking Alpha’s Quant Rating on Inventiva Historical earnings data for Inventiva Financial information for Inventiva Read the full article on Seeking Alpha For furthe...
2024-02-12 15:06:51 ET More on CymaBay, Gilead, etc. Gilead Sciences: Cheap For A Reason Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript Gilead Sciences, Inc. 2023 Q4 - Results - Earnings Call Presentation Gilead to acquire CymaBay for $32.50/sh...
2024-01-22 08:37:55 ET Rail Vision ( RVSN ) +96% Successfully Secures Approval and Certifications and for EU Railway Standards. Nustar Energy ( NS ) +23% to buy NuStar in all-stock deal valued at $7.3B. MSP Recovery ( LIFW ) +23% . North...
2023-12-08 08:20:25 ET MBIA ( MBI ) +66% declares extraordinary cash dividend; shares up premarket Volato Group ( SOAR ) +51% . FLJ Group ( FLJ ) +23% . MicroAlgo ( MLGO ) +15% . Eneti ( NETI ) +10% Announce Ext...
2023-11-27 10:34:03 ET More on Tharimmune, Inc. Financial information for Tharimmune, Inc. For further details see: Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug
2023-11-27 07:30:00 ET Summary Genfit is close to possible approval for its drug team-up with Ipsen, with positive Phase 3 readouts having been achieved. The company focuses on developing therapeutic products for liver diseases, currently with a primary focus on Primary Biliary Ch...
2023-11-19 09:52:24 ET Summary Today, we revisit CymaBay Therapeutics, a clinical stage biopharma company focused on developing therapies for liver and chronic diseases. The company's primary product candidate, seladelpar, has shown positive results in treating primary biliary cho...
News, Short Squeeze, Breakout and More Instantly...
GENFIT S.A. Company Name:
GNFT Stock Symbol:
NYSE Market:
Lakeland Industries Inc. (LAKE) is expected to report $0.3 for Q4 2024 Sekisui House Ltd. ADR (SKHSY) is expected to report for Q4 2024 Hingham Institution for Savings (HIFS) is expected to report for Q1 2024 GENFIT S.A. (GNFT) is expected to report for Q4 2023 Jewett-Cameron Trad...
Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF) PR Newswire Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical,...